Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.
Date
2023-06-28ICR Author
Author
Curigliano, G
Dent, R
Llombart-Cussac, A
Pegram, M
Pusztai, L
Turner, N
Viale, G
Type
Journal Article
Metadata
Show full item recordAbstract
Stratification of recurrence risk is a cornerstone of early breast cancer diagnosis that informs a patient's optimal treatment pathway. Several tools exist that combine clinicopathological and molecular information, including multigene assays, which can estimate risk of recurrence and quantify the potential benefit of different adjuvant treatment modalities. While the tools endorsed by treatment guidelines are supported by level I and II evidence and provide similar prognostic accuracy at the population level, they can yield discordant risk prediction at the individual patient level. This review examines the evidence for these tools in clinical practice and offers a perspective of potential future risk stratification strategies. Experience from clinical trials with cyclin D kinase 4/6 (CDK4/6) inhibitors in the setting of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer is provided as an illustrative example of risk stratification.
Collections
Subject
Science & Technology
Life Sciences & Biomedicine
Oncology
ENDOCRINE THERAPY
70-GENE SIGNATURE
TREATMENT DECISIONS
PROGNOSTIC VALUE
OPEN-LABEL
EXPRESSION
STAGE
INDEX
PALBOCICLIB
LETROZOLE
Research team
Molecular Oncology
Language
eng
Date accepted
2023-06-06
License start date
2023-06-28
Citation
npj Breast Cancer, 2023, 9 (1), pp. 56 -
Publisher
NATURE PORTFOLIO